Peter Lynch's "Chicken's Guide" to Biotech (And Why I Do the Opposite)
In 1993, Peter Lynch showed nervous investors how to play biotech without the risk. Buried in the same column was the real blueprint for microcap investing...
To read our full disclaimer, click here.
In 1993, Peter Lynch wrote a column called “A Chicken’s Guide to Biotech.”
It was written for people who liked the idea of biotech but couldn’t stomach the risk.
The premise was simple: here’s how to get exposure to the sector without betting on some tiny lab that might blow up overnight.
A chicken’s way out.
I’ve read that column more times than I can count.
And here’s the funny thing.
Buried inside Lynch’s “play it safe” advice is the exact framework I use to think about healthcare microcaps today.
He just told his readers not to use it.
Let me show you what I mean…
The Setup Hasn’t Changed in 30 Years
Lynch was writing in the middle of a biotech sell-off.
Investors had lost faith. They’d lost money.
And the roughly 225 publicly traded biotech companies of the era suddenly couldn’t raise a dime.
In his words, they could no longer “depend on the public generosity to keep them solvent.”
The new-issue market had shut down. The eager crowd of buyers had vanished.
So the cash-poor labs were forced into mergers, joint ventures, and licensing deals with richer partners - mostly the pharmaceutical giants.
It’s worth reading that twice, because it describes the biotech market almost perfectly right now.
A brutal drawdown. A frozen financing window. Dozens of small companies trading for less than the cash sitting in their bank accounts, forced to do deals just to survive.
To most investors, that’s a horror story.
I tend to see it differently.
Distress is what creates the mispricing. When good science is forced to sell itself cheaply, that’s often when the most interesting opportunities appear.
Lynch’s Chicken’s Way Out
Lynch’s first piece of advice was to buy the pharmaceutical giants.
The logic was sound. The giants had a problem - their blockbuster patents (Cardizem, Procardia, Ceclor) were expiring, and generics were eating into their margins.
But the biotech sell-off handed them a gift: the chance to buy cutting-edge science, with fresh patents, on the cheap.
So Lynch pointed readers toward names like Schering-Plough, which was spending $125 million a year on biotech R&D and had a licensing deal with Biogen for alpha interferon. It traded at about 15 times earnings, growing 15% a year.
Safe. Sensible. Diversified.
And it’s a perfectly reasonable way to invest.
It’s just not where the most dramatic outcomes tend to come from.
A large pharma giant that adds a promising biotech partnership doesn’t usually re-rate by a factor of ten.
The small company on the other side of that deal is a different matter.
The Part Almost Everyone Skips
Lynch then offered what he called the “reverse chicken’s approach.”
Look at the biotech companies being absorbed by the giants, or the ones doing the major joint ventures.
His reasoning is the most important idea in the whole column:
When Roche spent $2.1 billion to acquire 60% of Genentech, Lynch said it was “a pretty good sign there’s some value left in the remaining 40%.”
That’s the heart of it.
A deep-pocketed pharma giant, with armies of PhDs doing due diligence, validating the science by writing an enormous check - and the public market still pricing the rest at a discount.
Lynch said it was the Roche-Genentech deal in September 1990 that finally convinced him the biotech industry was for real.
It took four months for Genentech to begin climbing, from $21 to $39.
This is close to how I think about The Clinical Edge.
Let the giants and the specialists validate the science. Then look for the small, overlooked company where the market’s story still hasn’t caught up to the scientific reality.
Narrative dislocation. The market lags the science. That gap is the whole point.
The Real Blueprint: Amgen
The best part of Lynch’s column is the Amgen story, and it’s a masterclass in optionality.
Fidelity’s biotech analyst, Mike Gordon, spotted Amgen around 1989 and was begging the in-house managers to load up while it traded at $5 to $7.
When Amgen’s first real product, Epogen, got final FDA clearance, the stock hit $10.
By the end of 1991, it was $76.
Ten times your money in about two years.
But here’s the lesson Lynch wanted you to take away, and it’s one most investors get completely wrong:
“Just because the good news is already out doesn’t mean it’s too late to invest.”
Amgen roughly doubled again in 1991-92 - after it had already won its patent battles, after the FDA approval, after the “obvious” news was public.
The optionality didn’t disappear when the first catalyst hit. It carried on.
It’s a useful reminder that the instinct to sell the moment a thesis starts working is often the wrong one.
The Volatility Is Real
Lynch was honest about the pain, and it’s only fair to be the same.
Not long after Amgen reached $70, the entire biotech sector dropped - because one unrelated company failed an important clinical trial.
Amgen was dragged down in sympathy. $70 to $35. A $10 billion company cut to $5 billion, on news that had nothing to do with it.
In Lynch’s words:
“An investor in biotech shares has to have a strong stomach, and it helps to be farsighted as well.”
But what he says next is the part worth underlining, because it’s essentially a screen:
When the whole sector gets hit, look for bargains - “companies with share values close to their cash holdings.”
With one crucial filter to keep the risk contained.
Limit the search to companies that already have drugs on the market, or at least in clinical trials, with real revenue coming in.
Cash on the balance sheet. Real products. Actual revenue. Bought during a sector-wide panic.
Regular readers will recognise that, because it’s almost word for word how I screen for healthcare microcaps trading near or below their own cash.
Here is one here:
Lynch wrote the filter in 1993. It still works.
Where I Personally Go the Other Way
The way Lynch closes the column is, more or less, the way the masses have always been advised on biotech.
It’s too volatile. Too complex. Leave it to the professionals. Buy a diversified fund and don’t try to pick the small names.
There’s nothing wrong with that advice. But it is what almost everyone is told - and when the whole crowd is funnelled toward the same safe options, the giants and the funds and the index, the small overlooked companies get left for dead.
That neglect is the opportunity.
So my strategy deliberately goes the other way. Into the undiscovered, unloved corner of healthcare the masses are steered away from.
But going against the crowd without protection is just recklessness with extra steps.
So I take the very things Lynch said to look for in biotech and turn them into my margin of safety:
Cash on the balance sheet, a product on the market or in trials, and real revenue coming in - the exact filter Lynch laid out, so the downside is anchored to something tangible.
Multiple shots on goal - pipeline diversity, platform technology, more than one way for the thesis to work.
Real problems - genuine unmet medical need, a clear regulatory path, customers willing to pay.
Founder-led teams with their own money on the line.
Then comes the part that ties it all together: how I actually build a position.
I start small. The initial position is deliberately modest - sized so that if the thesis is simply wrong, it does no real damage to the portfolio.
I only add as catalysts approach and the data backs up the story.
And once a position is working, I’m in no rush to trim it.
That combination - operating where the crowd won’t, but insisting on cash, revenue, optionality and alignment before I do, then starting small and adding into strength - is the margin of safety.
It’s what lets me take controlled positions in an area everyone else is told to avoid.
The Takeaway
Peter Lynch wrote a guide for people who were nervous about biotech.
But, for me, a far more interesting approach was sitting in the same column the whole time.
Buy good science during a panic. Insist on cash on the balance sheet, real products, and real revenue. Let the giants validate the breakthroughs. Hold through the volatility. And think hard before cutting a position the moment it starts to work.
Lynch’s column was the careful, conventional route - the one the masses are pointed toward.
My strategy takes the opposite path on purpose: into the small, overlooked names the crowd is told to avoid, with cash, revenue, optionality and alignment as the margin of safety, and small, controlled position sizes as the seatbelt.
That corner of the market - small and overlooked healthcare companies - is exactly where this newsletter goes looking each week.
The Clinical Edge exists to do that work: 2-4 healthcare microcaps a month with asymmetric risk-reward, multiple shots on goal, aligned management, and mispriced optionality.
Paid membership is available here:
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.